2025
Association of stress-induced autonomic dysfunction with heart failure in individuals with stable coronary artery disease
Wang M, Liu C, Shah A, Ko Y, Lampert R, Sun Y, Moazzami K, Garcia M, Almuwaqqat Z, Najarro G, Sullivan S, Raggi P, Bremner J, Quyyumi A, Vaccarino V, Morris A, Shah A. Association of stress-induced autonomic dysfunction with heart failure in individuals with stable coronary artery disease. IJC Heart & Vasculature 2025, 59: 101694. DOI: 10.1016/j.ijcha.2025.101694.Peer-Reviewed Original ResearchStable coronary artery diseaseResting heart rate variabilityCoronary artery diseaseLow-frequency heart rate variabilityHF riskMental stress challengeHeart rate variabilityHeart failureIncreased risk of incidentAcute HFAutonomic dysfunctionRisk of incidentBackground Heart failureAssociated with higher riskArtery diseaseCox proportional hazards modelsStrong effect sizesDiagnosis of HFIncreased HF riskProportional hazards modelMedian Follow-UpInpatient settingStandard deviation decreaseHRV changesEvaluate heart rate variabilityAdvanced tissue-engineered pulsatile conduit using human induced pluripotent stem cell-derived cardiomyocytes
Luo H, Anderson C, Li X, Lu Y, Hoareau M, Xing Q, Fooladi S, Liu Y, Xu Z, Park J, Fallon M, Thomas J, Gruber P, Elder R, Mak M, Riaz M, Campbell S, Qyang Y. Advanced tissue-engineered pulsatile conduit using human induced pluripotent stem cell-derived cardiomyocytes. Acta Biomaterialia 2025 PMID: 40582540, DOI: 10.1016/j.actbio.2025.06.055.Peer-Reviewed Original ResearchSingle ventricle congenital heart defectsHuman induced pluripotent stem cell-derived cardiomyocytesPluripotent stem cell-derived cardiomyocytesStem cell-derived cardiomyocytesCell-derived cardiomyocytesCongenital heart defectsHuman umbilical arteryUmbilical arteryHeart defectsPulmonary circulationDecellularized human umbilical arteriesHeart tissueLife-threatening defectsLife-threatening disorderLong-term complicationsEngineered Heart TissueFontan surgeryFunctioning ventriclePrompt treatmentHeart failureSpontaneous beatingPump functionImprove outcomesPressure generationConventional treatmentLetter: Response to Feder et al., Use of Hospice and End-of-Life Care Quality Among Medical Centers with High Versus Lower Specialist Palliative Care Reach Among People with Heart Failure: An Observational Study
Feder S, Shamas T, Akgün K. Letter: Response to Feder et al., Use of Hospice and End-of-Life Care Quality Among Medical Centers with High Versus Lower Specialist Palliative Care Reach Among People with Heart Failure: An Observational Study. Journal Of Palliative Medicine 2025 PMID: 40533098, DOI: 10.1089/jpm.2025.0317.Peer-Reviewed Original ResearchProteins associated with rehospitalization, mortality and diuretic resistance in acutely decompensated heart failure
Hubbell K, Rao V, Scherzer R, Shlipak M, Ivery‐Miranda J, Bansal N, Cox Z, Testani J, Estrella M. Proteins associated with rehospitalization, mortality and diuretic resistance in acutely decompensated heart failure. ESC Heart Failure 2025 PMID: 40504107, DOI: 10.1002/ehf2.15342.Peer-Reviewed Original ResearchAcute decompensated heart failureDecompensated heart failureDiuretic responseHeart failureHF rehospitalizationRisk of HF rehospitalizationBiomarker modelAssociated with poor outcomesAssociated with decreased riskAssociated with increased riskAssociated with cardiometabolic diseasesAssociated with mortalityAssociated with rehospitalizationDiuretic resistanceMedian ageResistance cohortClinical factorsPoor outcomeSociodemographic/lifestyle factorsPrognostic toolCombined biomarkersCardiometabolic diseasesPatientsAmbulatory settingMortality riskInpatient Outcomes for Patients With Peripheral Artery Disease Hospitalized for Acute Myocardial Infarction.
Gusdorf J, Faridi K, Wang T, Mena-Hurtado C, Smolderen K, Rymer J, Curtis J, Li S, Secemsky E. Inpatient Outcomes for Patients With Peripheral Artery Disease Hospitalized for Acute Myocardial Infarction. Journal Of The American Heart Association 2025, 14: e040526. PMID: 40497502, DOI: 10.1161/jaha.124.040526.Peer-Reviewed Original ResearchConceptsAcute myocardial infarction typesPeripheral arterial diseaseAcute myocardial infarctionIn-Hospital MortalityPeripheral artery disease hospitalizationsIn-Hospital OutcomesAcute myocardial infarction hospitalizationsCardiac arrestHigh-risk populationAssociated with increased ratesLong-term riskRevascularized PatientsInpatient outcomesMultivariable adjustmentHeart failureArtery diseasePrimary outcomeAdverse cardiovascular outcomesUS sitesHeightened riskAge groupsSecondary end pointsSubgroup analysisDialysis initiationCoronary artery diseaseAssociation of Volume Overload With Kidney Function Outcomes Among Patients With Acute Decompensated Heart Failure
Moises A, Tighiouart H, Testani J, Tuttle M, Banlengchit R, Oka T, Lee K, Ferguson K, Sarnak H, Harding C, Kiernan M, Sarnak M, McCallum W. Association of Volume Overload With Kidney Function Outcomes Among Patients With Acute Decompensated Heart Failure. American Journal Of Kidney Diseases 2025 PMID: 40484339, DOI: 10.1053/j.ajkd.2025.03.026.Peer-Reviewed Original ResearchPulmonary capillary wedge pressureHigh central venous pressureCentral venous pressureAssociation of central venous pressureDecompensated heart failureRisk of dialysisVolume overloadInitiation of dialysisEGFR slopeHeart failureKidney functionDegree of volume overloadLow baseline kidney functionAcute decompensated heart failureRisk factorsAssociated with lower eGFRRight heart catheterizationCox proportional hazards regression modelsCapillary wedge pressureInitial central venous pressureAssociated with increased riskProportional hazards regression modelsBaseline kidney functionKidney function outcomesRestricted cubic splinesSodium chloride versus glucose solute as a volume replacement therapy for more effective decongestion in acute heart failure (SOLVRED‐AHF): A prospective, randomized, mechanistic study
Biegus J, Iwanek G, Testani J, Zymliński R, Fudim M, Guzik M, Gajewski P, Ponikowski P. Sodium chloride versus glucose solute as a volume replacement therapy for more effective decongestion in acute heart failure (SOLVRED‐AHF): A prospective, randomized, mechanistic study. European Journal Of Heart Failure 2025 PMID: 40455066, DOI: 10.1002/ejhf.3708.Peer-Reviewed Original ResearchAcute heart failureProximal tubular sodium reabsorptionCo-primary endpointsTubular sodium reabsorptionNaCl groupEffective decongestionDiuretic therapyUrine outputSodium reabsorptionHeart failureCumulative dose of furosemideGlucose groupFractional excretion of lithiumDose of furosemideMedian urine outputAbsolute distal reabsorptionVolume replacement therapyExcretion of lithiumSingle-blind studyInfusion of NaClInhibition of proximal tubular sodium reabsorptionFurosemide doseFluid overloadCumulative doseDecongestive effectUsing vascular biomarkers to assess heart failure event risk in hospitalized patients with and without AKI
Shi A, Andrawis A, Biswas A, Wilson F, Obeid W, Philbrook H, Go A, Ikizler T, Siew E, Chinchilli V, Hsu C, Garg A, Reeves W, Prince D, Bhatraju P, Coca S, Liu K, Kimmel P, Kaufman J, Wurfel M, Himmelfarb J, Parikh C, Mansour S. Using vascular biomarkers to assess heart failure event risk in hospitalized patients with and without AKI. BMC Nephrology 2025, 26: 271. PMID: 40457292, PMCID: PMC12131712, DOI: 10.1186/s12882-025-04169-1.Peer-Reviewed Original ResearchConceptsArea under the curveRisk of HF eventsHeart failureHF eventsHospitalized patientsPrediction of HFVascular biomarkersClinical modelHigher risk of HF eventsPrediction of HF eventsLevels of injury markersRates of heart failureDormant phenotypeAssociated with higher riskCox regression analysisHeart failure eventsCardiovascular disease risk factorsPost-hospitalizationDisease risk factorsSerum creatinineAKI patientsStratify patientsInjury markersLung diseaseClinical centers10-Year and 30-Year Risks of Cardiovascular Disease in the U.S. Population
Faridi K, Malik D, Essa M, Yang H, Spatz E, Krumholz H, Lu Y. 10-Year and 30-Year Risks of Cardiovascular Disease in the U.S. Population. Journal Of The American College Of Cardiology 2025, 85: 2239-2249. PMID: 40499978, DOI: 10.1016/j.jacc.2025.03.546.Peer-Reviewed Original ResearchConceptsRisk of cardiovascular diseaseAtherosclerotic CVDU.S. adultsU.S. populationHispanic adultsCardiovascular diseaseCVD riskLong-term riskNational Health and Nutrition Examination SurveyHealth and Nutrition Examination SurveyRisk of atherosclerotic CVDElevated 10-year riskLong-term risk of cardiovascular diseaseAdults aged >Nutrition Examination SurveyTotal cardiovascular diseaseRisk factor profileRisk of total cardiovascular diseaseSurvey-weighted prevalenceMiddle-aged adultsPrevent Cardiovascular DiseaseHeart failureExamination SurveyAge-standardizedBlack adultsMineralocorticoid receptor phase separation modulates cardiac preservation
Lei I, Sicim H, Gao W, Huang W, Noly P, Pergande M, Wilson M, Lee A, Liu L, Abou El Ela A, Jiang M, Saddoughi S, Pober J, Platt J, Cascalho M, Pagani F, Chen Y, Pitt B, Wang Z, Mortensen R, Ge Y, Tang P. Mineralocorticoid receptor phase separation modulates cardiac preservation. Nature Cardiovascular Research 2025, 4: 710-726. PMID: 40389663, DOI: 10.1038/s44161-025-00653-x.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsCell Cycle ProteinsCold IschemiaHeart TransplantationHistone Deacetylase 1HumansKidneyLiverLungMaleMiceMice, Inbred C57BLMineralocorticoid Receptor AntagonistsMyocytes, CardiacNuclear ProteinsOrgan PreservationPhase SeparationReceptors, MineralocorticoidTissue DonorsTranscription FactorsConceptsMineralocorticoid receptorDonor heartsHistone deacetylase 1Bromodomain-containing 4Gold standard treatmentEnd-stage heart failureCold ischemic timeShortage of donor heartsExpressed MRDonor cardiomyocytesHuman donor heartsHeart transplantationStandard treatmentIschemic timeHeart failureCardiac preservationSolid organsPharmacological inhibitionCold preservationPreserving biologyHeartSerum chloride and the response to combining loop and thiazide diuretics for acute heart failure: the ALCALOTIC study
Núñez J, Miñana G, Villalonga M, Asenjo M, Carrera M, Epelde F, Gil M, Chivite D, Contra A, Pla X, Casado J, Miró Ò, de la Espriella R, Testani J, Trullàs J. Serum chloride and the response to combining loop and thiazide diuretics for acute heart failure: the ALCALOTIC study. Internal And Emergency Medicine 2025, 1-11. PMID: 40379935, DOI: 10.1007/s11739-025-03961-z.Peer-Reviewed Original ResearchAcute heart failureHeart failureDiuretic responseSerum chlorideThiazide diureticsWeight lossAssociated with smaller weight lossPatients admitted with acute heart failurePathophysiology of heart failureIn-hospital weight lossAssociated with higher weight lossObservational cohort studyDiuretic resistanceHF prognosisThiazideCohort studyDiureticsPatientsHyperchloraemiaOverall populationHypochloraemiaClinical sitesSerumSmall weight lossFailureArtificial Intelligence in the Management of Heart Failure
Cheema B, Hourmozdi J, Kline A, Ahmad F, Khera R. Artificial Intelligence in the Management of Heart Failure. Journal Of Cardiac Failure 2025 PMID: 40345521, DOI: 10.1016/j.cardfail.2025.02.020.Peer-Reviewed Original ResearchArtificial intelligenceState-of-the-art algorithmsData privacy concernsState-of-the-artManagement of heart failureAI-based toolsElectronic health recordsAI solutionsMultimodal dataHeart failureHealth recordsIntegration challengesHeart failure syndromeStructural heart diseaseHeart failure treatmentIntelligenceImplementation challengesModel performanceModel governanceAdvanced diseaseFailure syndromeCardiomyopathy diagnosisFailure treatmentRisk factorsHeart diseaseOR1-7 | Association of Guideline-directed Medical Therapy Agents and Rates of Amputation in Patients with Chronic Heart Failure and Chronic Limb Threatening Ischemia
Kwaah P, Mensah S, Carboo A, Hu J, Altin S. OR1-7 | Association of Guideline-directed Medical Therapy Agents and Rates of Amputation in Patients with Chronic Heart Failure and Chronic Limb Threatening Ischemia. Journal Of The Society For Cardiovascular Angiography & Interventions 2025, 4: 102658. DOI: 10.1016/j.jscai.2025.102658.Peer-Reviewed Original ResearchDecongestion in heart failure: medical and device therapies
Cox Z, Damman K, Testani J. Decongestion in heart failure: medical and device therapies. Nature Reviews Cardiology 2025, 1-17. PMID: 40295876, DOI: 10.1038/s41569-025-01152-z.Peer-Reviewed Original ResearchHeart failure symptomsHeart failureDevice therapyFailure symptomsPersistent heart failure symptomsDesign of clinical trialsImplementing novel therapiesHeart failure outcomesMagnitude of benefitImprove decongestionPrimary therapyLoop diureticsResidual congestionNovel therapiesAdverse outcomesClinical trialsTherapyMedical strategiesPredominant causeFailure outcomesHospital readmissionHospitalTargeting congestionDecongestionHeartNatriuretic response prediction equation for use with oral diuretics in heart failure
Ivey-Miranda J, Rao V, Cox Z, Moreno-Villagomez J, Mastache D, Collins S, Testani J. Natriuretic response prediction equation for use with oral diuretics in heart failure. European Heart Journal 2025, 46: 2410-2418. PMID: 40272149, PMCID: PMC12208776, DOI: 10.1093/eurheartj/ehaf268.Peer-Reviewed Original ResearchConceptsMechanisms of diuretic resistanceArea under the curvePoor diuretic responseDiuretic responseHeart failureDiuretic doseOral diureticsNatriuretic responseHF patient cohortsLoop diuretic doseOral loop diureticsUrine samplesTimed urine collectionsOral loopDiuretic resistanceLoop diureticsDiuretic administrationUrine volumePatient cohortUrine collectionStudy visitsDiureticsPatientsUrineDoseComputational Phenomapping of Randomized Clinical Trial Participants to Enable Assessment of Their Real-World Representativeness and Personalized Inference
Thangaraj P, Oikonomou E, Dhingra L, Aminorroaya A, Jayaram R, Suchard M, Khera R. Computational Phenomapping of Randomized Clinical Trial Participants to Enable Assessment of Their Real-World Representativeness and Personalized Inference. Circulation Cardiovascular Quality And Outcomes 2025, 18: e011306. PMID: 40261065, PMCID: PMC12203226, DOI: 10.1161/circoutcomes.124.011306.Peer-Reviewed Original ResearchConceptsElectronic health record patientElectronic health recordsDistance metricRandomized clinical trialsElectronic health record dataMachine learning methodsYale New Haven Health SystemElectronic health record cohortRandomized clinical trial participantsLearning methodsHeart failureClinical trial participationTOPCAT participantsReal worldMultidimensional metricRCT participantsHealth recordsTreatment effectsHealth systemCharacteristics of patientsRandomized clinical trial cohortsTrial participantsMetricsUnited StatesNovel statisticImmune Checkpoint Inhibitor Myocarditis and Left Ventricular Systolic Dysfunction
Chen Y, Dolladille C, Rao A, Palaskas N, Deswal A, Lehmann L, Cautela J, Courand P, Hayek S, Zhu H, Cheng R, Alexandre J, Baldassarre L, Roubille F, Laufer-Perl M, Asnani A, Ederhy S, Tamura Y, Francis S, Gaughan E, Johnson D, Flint D, Rainer P, Bailly G, Ewer S, Aras M, Arangalage D, Cariou E, Florido R, Peretto G, Zadok O, Akhter N, Narezkina A, Levenson J, Liu Y, Crusz S, Issa N, Piriou N, Leong D, Sandhu S, Turker I, Moliner P, Obeid M, Heinzerling L, Chang W, Stewart A, Venkatesh V, Du Z, Yadavalli A, Kim D, Chandra A, Zhang K, Power J, Moslehi J, Salem J, Zaha V, Registry I. Immune Checkpoint Inhibitor Myocarditis and Left Ventricular Systolic Dysfunction. JACC CardioOncology 2025, 7: 234-248. PMID: 40246381, PMCID: PMC12046861, DOI: 10.1016/j.jaccao.2025.01.020.Peer-Reviewed Original ResearchLeft ventricular ejection fractionImmune checkpoint inhibitorsPredictors of left ventricular ejection fractionAll-Cause MortalityHeart failureAssociated with 30-day all-cause mortalityDocumented LVEFAssociated with left ventricular ejection fractionReduced left ventricular ejection fractionImmune checkpoint inhibitor initiationImmune checkpoint inhibitor myocarditisHistory of heart failurePre-existing heart failureTransforming cancer treatmentVentricular ejection fractionCox proportional hazards modelsBody mass indexMultivariate logistic regressionTime of hospitalizationProportional hazards modelCheckpoint inhibitorsMyositis symptomsChest radiationCardiotoxic therapiesEjection fractionGaps in care delivery for patients with heart failure: A qualitative study of patients with multiple readmissions
Latif Z, Makuvire T, Feder S, Garan A, Pinzon P, Warraich H. Gaps in care delivery for patients with heart failure: A qualitative study of patients with multiple readmissions. Journal Of Hospital Medicine 2025 PMID: 40223191, DOI: 10.1002/jhm.70051.Peer-Reviewed Original ResearchEffective care deliveryCare deliveryPatients admitted with HF exacerbationsQualitative studyQualitative study of patientsPatients expressed frustrationHF exacerbationRecurrent admissionsHigh-risk populationDischarge educationSemistructured interviewsThematic analysisTargeted interventionsHospital readmissionInterview contentHeart failureReadmission ratesMedical chartsCareCommunication challengesStudy of patientsReadmissionPatient's disease courseInterviewsManagement of patientsFirst-in-Human Implantable Inferior Vena Cava Sensor for Remote Care in Heart Failure FUTURE-HF
Kalra P, Gogorishvili I, Khabeishvili G, Málek F, Toman O, Critoph C, Flett A, Cowburn P, Mehra M, Sheridan W, Britton J, Buxo T, Kealy R, Kent A, Greene B, Guha K, Gardner R, Loke I, Vazir A, Brugts J, Gray A, Testani J, Damman K. First-in-Human Implantable Inferior Vena Cava Sensor for Remote Care in Heart Failure FUTURE-HF. JACC Heart Failure 2025, 13: 1000-1010. PMID: 40208140, DOI: 10.1016/j.jchf.2025.01.019.Peer-Reviewed Original ResearchConceptsInferior vena cavaHeart failureIVC areaTechnical endpointsElevated natriuretic peptide levelsN-terminal pro-B-type natriuretic peptidePro-B-type natriuretic peptideAnalysis of clinical outcomesFirst-in-human experienceFirst-in-human studyMarkers of congestionOptimal HF treatmentReduce HF eventsNYHA functional classProcedure-related complicationsNatriuretic peptide levelsNatriuretic peptideVena cavaSafety endpointsHF hospitalizationClinical findingsClinical outcomesProcedural successFollow-upPrimary safetyCoronary artery bypass surgery improves restricted mean survival time in patients with ischemic cardiomyopathy
Reinhardt S, Huang H, Parise H, Ahmad T, Velazquez E, Faridi K. Coronary artery bypass surgery improves restricted mean survival time in patients with ischemic cardiomyopathy. American Heart Journal Plus Cardiology Research And Practice 2025, 54: 100538. PMID: 40485767, PMCID: PMC12142554, DOI: 10.1016/j.ahjo.2025.100538.Peer-Reviewed Original ResearchCoronary Artery Bypass GraftingAll-Cause MortalityIschemic cardiomyopathyMean survival timeMedical therapyRestricted mean survival timeClinical trialsEndpoint of all-cause mortalityInternational multicenter randomized clinical trialSurvival timeCoronary artery bypass surgeryOptimal medical therapyMulticenter Randomized Clinical TrialBenefit of coronary artery bypass graftingEffect of coronary artery bypass graftingIschemic heart failureArtery bypass surgeryCox proportional hazards modelsArtery Bypass GraftingRandomized clinical trialsProportional hazards modelSurgical treatmentBypass surgeryHeart failureBypass Grafting
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply